Identifying the underlying cause of your patient’s chronic anemia can make a big difference to your patient’s life. That’s why Agios Pharmaceuticals has partnered with Revvity Omics to offer Anemia ID: a free genetic testing program. Anemia ID provides a next-generation sequencing (NGS) panel for a wide range of rare hereditary anemias.
Systemic Mastocytosis (SM) is a rare disorder characterized by neoplastic proliferation of mast cells driven by the KIT D816V mutation in greater than 90% of cases.1 Early biomarker testing using a non-invasive, highly sensitive, and quantitative KIT D816V test may reduce a patient’s time to diagnosis. This test is provided by Labcorp Oncology for eligible patients at no-charge through the sponsored testing program from Blueprint Medicines.*
